Skip to main content
SpringerLink
Log in

ICDs, VADs, and Total Artificial Heart Implantation

  • Chapter
  • First Online:
Psychosocial Care of End-Stage Organ Disease and Transplant Patients

  • 893 Accesses

Abstract

Device therapy for heart failure has evolved rapidly over recent years and has become an important element in reducing mortality risk, improving quality of life and functional capacity for patients with heart failure. Therapies such as implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are aimed at reducing risk of sudden cardiac death and improving functional status. Heart failure is a progressive condition and, despite significant advances in medical therapy, may still develop into an end-stage state requiring consideration for advanced therapies such as mechanical circulatory support (MCS) and heart transplantation to prolong survival and improve quality of life. As with any procedure, each therapy poses its own risks and benefits which must be carefully weighed in each patient. Some, such as MCS, require significant psychosocial support in order to best achieve a positive outcome with maximal benefit to the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anderson KP, DeCamilla J, Moss AJ. Clinical significance of ventricular tachycardia (3 beats or longer) detected during ambulatory monitoring after myocardial infarction. Circulation. 1978;57:890–7.

    Article  CAS  Google Scholar 

  2. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. N Engl J Med. 1991;324:781–8.

    Article  CAS  Google Scholar 

  3. Rowley CP, Gold MR. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2012;5:587–93.

    Article  Google Scholar 

  4. Epstein AE, DiMarco JP, Ellenbogen KA, Estes M, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device based therapy for cardiac rhythm abnormalities. J Am Coll Cardiol. 2013;61:e6–75.

    Article  Google Scholar 

  5. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Greene HL, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J. 2000;21:2071–8.

    Article  CAS  Google Scholar 

  6. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.

    Article  CAS  Google Scholar 

  7. Powell AC, Fuchs T, Finkelstein DM, Garan H, Cannom DS, McGovern BA, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation. 1993;88:1083–92.

    Article  CAS  Google Scholar 

  8. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study Hamburg (CASH). Circulation. 2000;102:748–54.

    Article  CAS  Google Scholar 

  9. Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195–203.

    Article  CAS  Google Scholar 

  10. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med. 1996;335:1933–40.

    Article  CAS  Google Scholar 

  11. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.

    Article  Google Scholar 

  12. Bardy G, Lee K, Mark D, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.

    Article  CAS  Google Scholar 

  13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, et al. 2013 ACCF/AHA guideline for management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    Article  Google Scholar 

  14. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart Failure. N Engl J Med. 2002;246:1845–53.

    Article  Google Scholar 

  15. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.

    Article  Google Scholar 

  16. Van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol. 2011;58:995–1000.

    Article  Google Scholar 

  17. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116:1349–55.

    Article  Google Scholar 

  18. Van Rees JB, Borleffs JW, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors and impact on mortality. J Am Coll Cardiol. 2011;57:556–62.

    Article  Google Scholar 

  19. Sears S, Conti J. Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. Clin Cardiol. 2003;26:107–11.

    Article  Google Scholar 

  20. Habibovic M, van den Broek KC, Alings M, Van der Voort PH, Denollet J. Posttraumatic stress 18 months following cardioverter defibrillator implantation: shocks, anxiety and personality. Health Psychol. 2012;31(2):186–93.

    Article  Google Scholar 

  21. Köbe J, Hucklenbroich K, Geisendörfer N, Bettin M, Frommeyer G, Reinke F, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol. 2017;106:317–21.

    Article  Google Scholar 

  22. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al., for the MADIT-RIT Trial investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–83.

    Article  CAS  Google Scholar 

  23. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States: 1993–2008. J Am Coll Cardiol. 2011;58:1001–6.

    Article  Google Scholar 

  24. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey RJ, et al. The registry of the international society for heart and lung transplantation: thirty-third adult heart transplantation report – 2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1149–205.

    Article  Google Scholar 

  25. Interagency Registry for Mechanically Assisted Circulatory Support Website. http://www.uab.edu/medicine/intermacs/about-us. Accessed 26 Feb 2017.

  26. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34:1495–504.

    Article  Google Scholar 

  27. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.

    Article  CAS  Google Scholar 

  28. Miller LW, Pagani FD, Russell SD, John R, Boyel AJ Aaronson KD, et al., for the HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.

    Article  CAS  Google Scholar 

  29. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-US Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS. J Am Coll Cardiol. 2011;57:1890–8.

    Article  Google Scholar 

  30. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al., for the HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.

    Article  CAS  Google Scholar 

  31. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al., for the HeartMate II Clinical Investigators. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry. J Am Coll Cardiol. 2014;63:1751–7.

    Google Scholar 

  32. Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, et al., for the HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191–200.

    Article  Google Scholar 

  33. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376:451–60.

    Article  Google Scholar 

  34. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351:859–67.

    Article  CAS  Google Scholar 

  35. FDA Approves the Freedom Portable Driver that Powers the SynCardia Total Artificial Heart. http://www.syncardia.com/2014-press-releases/fda-approves-the-freedom-portable-driver-that-powers-the-syncardia-total-artificial-heart.html. Accessed 26 Feb 2017.

  36. Lampert BC, Tueteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015;34:1123–30.

    Article  Google Scholar 

  37. Kapelios CJ, Charitos C, Kaldara E, Malliaras K, Nana E, Pantsios C, et al. Late-onset right ventricular dysfunction after mechanical support by a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2015;34:1604–10.

    Article  Google Scholar 

  38. Schaffer JM, Allen JG, Weiss ES, Arnaoutakis GJ, Patel ND, Russell SD, et al. Infectious complications after pulsatile and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant. 2011;30:164–74.

    Article  Google Scholar 

  39. Gordon RJ, Weiberg A, Pagani F, Slaughter MS, Pappas PS, Naka Y, et al. Prospective multicenter study of ventricular assist device infections. Circulation. 2013;127:691–702.

    Article  Google Scholar 

  40. Crow S, John R, Boyle A, Shumway S, Liao K, Colvin-Adams M, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208–15.

    Article  CAS  Google Scholar 

  41. Suarez J, Patel CB, Felker M, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4:779–84.

    Article  Google Scholar 

  42. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidly E, et al., for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:214–48.

    Google Scholar 

  43. Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) an analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33:12–22.

    Article  Google Scholar 

  44. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.

    Article  CAS  Google Scholar 

  45. Kirklin JK, Naftel DC, Kormos RL, Myers S, Acker MA, Rogers J, et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS registry. J Heart Lung Transplant. 2015;34:1515–26.

    Article  Google Scholar 

  46. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias TJ. The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail. 2010;3:668–74.

    Article  Google Scholar 

  47. Jorde UP, Uriel N, Nahumi N, Bejar D, Gonzalez-Costello J, Thomas SS, et al. Prevalence, significance, and management of aortic insufficiency in continuous flow left ventricular assist device recipients. Circ Heart Fail. 2014;7:310–9.

    Article  Google Scholar 

  48. Park SW, Uriel N, Takayama H, Cappleman S, Song R, Colombo PC, et al. Prevalence of de novo aortic insufficiency in left ventricular assist device-supported patients. J Heart Lung Transplant. 2010;29:1172–6.

    Article  Google Scholar 

  49. Atkins BZ, Hashmi ZA, Ganapathi AM, Harrison JK, Hughes GC, Rogers JG, et al. Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. Cardiovasc Surg. 2013;146:1247–52.

    Google Scholar 

  50. Rizzieri AG, Verheijde JL, Rady MY, McGregor JL. Ethical challenges with the left ventricular assist device as a destination therapy. Philos Ethics Humanit Med. 2008;3:20. https://doi.org/10.1186/1747-5341-3-20.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Dunlay SM, Strand JJ, Wordingham SE, Stulak JM, Luckhardt AJ, Swetz KM. Dying with a left ventricular assist device as destination therapy. Circ Heart Fail. 2016;9:e003096. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003096.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Thompson JS, Matlock DD, McIlvennan CK, Jenkins AR, Allen LA. Development of a decision aid for patients with advanced heart failure considering a destination therapy left ventricular assist device. JACC Heart Fail. 2015;3:965–76.

    Article  Google Scholar 

  53. Swetz KM, Freeman MR, AbouEzzeddine OF, Carter KA, Boilson BA, Ottenberg AL, et al. Palliative medicine consultation for preparedness planning in patients receiving left ventricular assist devices as destination therapy. Mayo Clin Proc. 2011;86:493–500.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sutter Health CPMC Center for Advanced Heart Failure Therapies, San Francisco, CA, USA

    Jared J. Herr

Authors
  1. Jared J. Herr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jared J. Herr .

Editor information

Editors and Affiliations

  1. Stanford University School of Medicine, Stanford, CA, USA

    Yelizaveta Sher

  2. Stanford University School of Medicine, Stanford, CA, USA

    José R. Maldonado

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Herr, J.J. (2019). ICDs, VADs, and Total Artificial Heart Implantation. In: Sher, Y., Maldonado, J. (eds) Psychosocial Care of End-Stage Organ Disease and Transplant Patients. Springer, Cham. https://doi.org/10.1007/978-3-319-94914-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-94914-7_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-94913-0

  • Online ISBN: 978-3-319-94914-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation